Viking Therapeutics - VKTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 218.30 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.77
▲ +0.05 (1.34%)

This chart shows the closing price for VKTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Viking Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VKTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VKTX

Analyst Price Target is $12.00
▲ +218.30% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $12.00, with a high forecast of $15.00 and a low forecast of $10.00. The average price target represents a 218.30% upside from the last price of $3.77.

This chart shows the closing price for VKTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Viking Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/1/2022OppenheimerLower Target$10.00Low
10/27/2022Raymond JamesBoost TargetOutperform$10.00 ➝ $11.00Low
4/28/2022Roth CapitalLower Target$20.00 ➝ $15.00High
2/10/2022Raymond JamesLower TargetOutperform$13.00 ➝ $10.00High
11/12/2021Maxim GroupInitiated CoverageBuy$14.00High
11/8/2021BMO Capital MarketsReiterated RatingBuy$15.00Medium
11/3/2021SVB LeerinkReiterated RatingOutperformHigh
10/29/2021William BlairReiterated RatingBuyHigh
7/29/2021Raymond JamesBoost TargetOutperform$12.00 ➝ $13.00High
6/20/2021SVB LeerinkInitiated CoverageBuy$18.00Low
6/18/2021B. RileyReiterated RatingBuy$15.00High
6/17/2021HC WainwrightReiterated RatingBuy$21.00Medium
5/25/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$27.00 ➝ $12.00High
5/3/2021SVB LeerinkReiterated RatingBuy$18.00High
1/22/2021Stifel NicolausReiterated RatingBuy$13.00Low
10/29/2020Raymond JamesBoost TargetStrong-Buy$25.00 ➝ $27.00Medium
9/11/2020William BlairReiterated RatingBuyLow
9/10/2020B. RileyReiterated RatingBuy$15.00High
9/1/2020BTIG ResearchBoost TargetBuy$9.00 ➝ $12.00High
8/31/2020Chardan CapitalBoost TargetBuy$15.00 ➝ $20.00Medium
8/28/2020HC WainwrightBoost TargetBuy$18.00 ➝ $21.00High
8/6/2020Raymond JamesReiterated RatingBuy$25.00Medium
7/30/2020B. RileyReiterated RatingBuy$12.00High
7/29/2020Chardan CapitalReiterated RatingBuy$15.00High
7/29/2020OppenheimerReiterated RatingBuy$12.00High
7/29/2020Stifel NicolausReiterated RatingBuy$14.00High
6/4/2020BMO Capital MarketsInitiated CoverageOutperform$14.00Medium
5/5/2020Chardan CapitalInitiated CoverageBuy$15.00Medium
5/4/2020B. RileyLower TargetBuy$16.00 ➝ $12.00High
5/2/2020Maxim GroupInitiated CoverageBuy$14.00High
5/1/2020OppenheimerInitiated CoverageBuy$12.00High
5/1/2020Raymond JamesLower TargetStrong-Buy$41.00 ➝ $25.00High
5/1/2020BTIG ResearchInitiated CoverageBuy$9.00High
4/30/2020Stifel NicolausReiterated RatingBuy$14.00High
4/3/2020William BlairReiterated RatingBuyLow
3/18/2020William BlairReiterated RatingBuyHigh
2/27/2020HC WainwrightLower TargetBuy$31.00 ➝ $18.00High
1/2/2020SVB LeerinkReiterated RatingOutperformMedium
11/21/2019B. RileyInitiated CoverageBuy$16.00Low
11/6/2019Maxim GroupReiterated RatingBuy$14.00Low
11/5/2019HC WainwrightReiterated RatingBuy$31.00High
8/2/2019HC WainwrightReiterated RatingBuy$31.00High
7/16/2019CIBCInitiated CoverageOutperform ➝ Outperform$12.00Low
7/16/2019OppenheimerInitiated CoverageOutperform$12.00 ➝ $12.00High
7/15/2019CitigroupInitiated CoverageOutperformHigh
6/25/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$14.00High
4/11/2019HC WainwrightReiterated RatingBuy$31.00Medium
3/29/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$10.00 ➝ $21.00High
3/29/2019William BlairReiterated RatingOutperformHigh
3/14/2019Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$43.00 ➝ $40.00Low
3/14/2019William BlairReiterated RatingOutperformHigh
3/14/2019Maxim GroupLower TargetBuy$28.00 ➝ $20.00High
2/22/2019SVB LeerinkInitiated CoverageMarket Perform$10.00Medium
12/11/2018B. RileyInitiated CoverageBuy ➝ Buy$16.00Low
11/19/2018Raymond JamesUpgradeOutperform ➝ Strong-Buy$43.00High
11/13/2018William BlairReiterated RatingBuyHigh
11/9/2018Roth CapitalSet TargetBuy$23.00Medium
11/8/2018Maxim GroupReiterated RatingBuy$28.00High
11/8/2018HC WainwrightReiterated RatingBuy$31.00N/A
10/1/2018William BlairReiterated RatingMarket PerformHigh
10/1/2018HC WainwrightSet TargetBuy$31.00High
9/19/2018Raymond JamesSet TargetBuy$43.00Low
9/19/2018Roth CapitalBoost TargetBuy$13.00 ➝ $24.00High
9/19/2018SunTrust BanksBoost TargetBuy$28.00High
9/18/2018Maxim GroupReiterated RatingBuy ➝ Buy$14.00 ➝ $28.00High
9/18/2018Raymond JamesReiterated RatingOutperform ➝ Outperform$15.00 ➝ $43.00High
9/18/2018HC WainwrightSet TargetBuy ➝ Buy$15.00 ➝ $28.00High
8/10/2018William BlairReiterated RatingOutperformHigh
8/10/2018HC WainwrightReiterated RatingBuy$15.00High
7/20/2018SunTrust BanksInitiated CoverageBuy$14.00High
6/28/2018Raymond JamesInitiated CoverageOutperform$15.00Medium
6/1/2018Roth CapitalBoost TargetBuy$7.50 ➝ $13.00Low
6/1/2018LaidlawBoost TargetBuy$10.00 ➝ $15.00High
6/1/2018HC WainwrightBoost TargetBuy ➝ Buy$11.00 ➝ $15.00High
5/31/2018Maxim GroupReiterated RatingBuy ➝ Buy$8.00 ➝ $14.00High
5/10/2018HC WainwrightSet TargetBuy$11.00High
5/10/2018Maxim GroupSet TargetBuy$8.00High
4/30/2018William BlairInitiated CoverageOutperformLow
3/26/2018HC WainwrightReiterated RatingBuy ➝ Buy$11.00High
3/8/2018Roth CapitalSet TargetBuy$8.00High
3/8/2018Maxim GroupReiterated RatingBuy$8.00High
2/2/2018Maxim GroupReiterated RatingBuy$8.00Low
12/12/2017Maxim GroupSet TargetBuy$8.00Low
(Data available from 12/7/2017 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
5/11/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/7/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Viking Therapeutics logo
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $3.77
Low: $3.69
High: $3.79

50 Day Range

MA: $3.78
Low: $2.71
High: $4.47

52 Week Range

Now: $3.77
Low: $2.02
High: $5.32

Volume

8,777 shs

Average Volume

743,409 shs

Market Capitalization

$289.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.43

Frequently Asked Questions

What sell-side analysts currently cover shares of Viking Therapeutics?

The following Wall Street sell-side analysts have issued reports on Viking Therapeutics in the last twelve months: Oppenheimer Holdings Inc., Raymond James, Roth Capital, and StockNews.com.
View the latest analyst ratings for VKTX.

What is the current price target for Viking Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Viking Therapeutics in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 222.6%. Roth Capital has the highest price target set, predicting VKTX will reach $15.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $10.00 for Viking Therapeutics in the next year.
View the latest price targets for VKTX.

What is the current consensus analyst rating for Viking Therapeutics?

Viking Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VKTX will outperform the market and that investors should add to their positions of Viking Therapeutics.
View the latest ratings for VKTX.

What other companies compete with Viking Therapeutics?

How do I contact Viking Therapeutics' investor relations team?

Viking Therapeutics' physical mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company's listed phone number is (858) 704-4660 and its investor relations email address is [email protected] The official website for Viking Therapeutics is www.vikingtherapeutics.com. Learn More about contacing Viking Therapeutics investor relations.